Articles about Sonoma Biotherapeutics

Seattle’s Sonoma Biotherapeutics receives $45M milestone payment

Sonoma Biotherapeutics on Wednesday announced that it received a $45 million payment from Regeneron Pharmaceuticals for meeting a significant milestone… Read More

Sonoma Bio celebrates new Seattle waterfront R&D center for autoimmune disease research

Sonoma Biotherapeutics on Monday hosted a ribbon cutting ceremony at its new research and development center and office space on… Read More

Tech Moves: Adaptive Biotechnologies COO departing; Sana adds leaders; and more

— Mark Adams is stepping down as chief operating officer of Adaptive Biotechnologies, the company said today in a regulatory… Read More

Sonoma Bio inks $75M deal with Regeneron to advance cell therapies against autoimmunity

The news: Sonoma Biotherapeutics is partnering with Regeneron to co-develop cell therapies for Crohn’s disease and other autoimmune conditions. The… Read More

Biotech industry leaders share cautious optimism for 2023 amid downturn and layoffs

Sujal Patel has been here before. He weathered the 2009 recession as CEO of Isilon Systems, coming out the other… Read More

Sonoma Biotherapeutics raises $265M to advance therapies for autoimmune, inflammatory diseases

Seattle and South San-Francisco based preclinical biotech company Sonoma Biotherapeutics has raised $265 million in new funding, the company announced… Read More